ABCELLERA BIOLOGICS INC

NASDAQ: ABCL (AbCellera Biologics Inc.)

Last update: 17 Sep, 2024, 7:52AM

2.79

0.11 (3.92%)

Previous Close 2.68
Open 2.68
Volume 219,334
Avg. Volume (3M) 1,899,582
Market Cap 820,644,800
Price / Sales 25.96
Price / Book 0.800
52 Weeks Range
2.34 (-16%) — 6.06 (117%)
Earnings Date 31 Oct 2024 - 4 Nov 2024
Operating Margin (TTM) -1,439.42%
Diluted EPS (TTM) -0.610
Quarterly Revenue Growth (YOY) -1.40%
Total Debt/Equity (MRQ) 6.62%
Current Ratio (MRQ) 9.34
Operating Cash Flow (TTM) -120.17 M
Levered Free Cash Flow (TTM) -105.58 M
Return on Assets (TTM) -13.26%
Return on Equity (TTM) -15.55%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock AbCellera Biologics Inc. Bearish Bearish

AIStockmoo Score

-0.5
Analyst Consensus 3.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages -5.0
Technical Oscillators 2.0
Average -0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ABCL 821 M - - 0.800
VIR 2 B - - 1.17
FTRE 2 B - - 1.08
SYRE 1 B - - 7.32
SPRY 1 B - - 5.10
NTLA 1 B - - 1.08

AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 27.93%
% Held by Institutions 39.65%

Ownership

Name Date Shares Held
Founders Fund Vii Management, Llc 30 Jun 2024 3,773,530
Guardian Capital Advisors Lp 30 Jun 2024 1,786,414
52 Weeks Range
2.34 (-16%) — 6.06 (117%)
Price Target Range
4.00 (43%) — 12.00 (330%)
High 12.00 (Stifel, 330.88%) Buy
Median 8.00 (187.25%)
Low 4.00 (Keybanc, 43.63%) Buy
Average 8.00 (187.25%)
Total 2 Buy
Avg. Price @ Call 2.88
Firm Date Target Price Call Price @ Call
Keybanc 08 Jan 2025 4.00 (43.63%) Buy 3.03
Stifel 05 Nov 2024 12.00 (330.88%) Buy 2.72

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria